Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT04459416 · ClinicalTrials.gov registry record · Phase 3
Managing Pain and Symptom Burden Caused by Chemotherapy in People With Myeloma or Lymphoma
A Phase 3 study of Multiple Myeloma and Non-Hodgkin Lymphoma, sponsored by Memorial Sloan Kettering Cancer Center.
- Active
- Registry status
- Phase 3
- Development phase
- 299
- Enrollment target
- 3
- Study locations
NCT04459416 is a Phase 3 study of Multiple Myeloma and Non-Hodgkin Lymphoma that is active but no longer recruiting, run by Memorial Sloan Kettering Cancer Center. The registered enrollment target is 299 participants, below the 546-participant average among 438 other Multiple Myeloma trials with a reported enrollment target (45% lower). The trial reports 3 study locations across 2 states.
The verdict
NCT04459416, a Phase 3 study of Multiple Myeloma and Non-Hodgkin Lymphoma, is active but no longer recruiting, sponsored by Memorial Sloan Kettering Cancer Center.
- ACTIVE NOT RECRUITING
- Registry status
- Phase 3
- Development phase
- 299 participants
- Enrollment target
- 3
- Study locations
Study Summary
The purpose of this study is to find out whether acupuncture treatments can reduce the need for opioid medication when managing pain caused by chemotherapy. The study will compare the effects of adding acupuncture to usual pain management with those of usual pain management alone, in reducing opioid use by relieving pain. Researchers also want to find out more about the effects of acupuncture treatments on other symptoms caused by cancer treatments and quality of life.
Conditions Studied
Interventions
- OTHER Acupuncture
- OTHER Assessments
- DRUG opioid
Study Locations (3)
Washington
- Fred Hutchinson Cancer Research Center - Seattle
- Seattle Cancel Care Alliance (Data Collection Only) - Seattle
New York
- Memorial Sloan Kettering Cancer Center - New York
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 299 participants |
| Start Date | 2020-06-30 |
| Est. Completion | 2026-06 |
| Phase | Phase 3 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT04459416
The ClinicalTrials.gov registry entry for NCT04459416 describes a study currently listed as active not recruiting, categorized as Phase 3. The registered enrollment target is 299 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 546-participant average among 438 other Multiple Myeloma trials with a reported enrollment target (45% lower). The listed sponsor is Memorial Sloan Kettering Cancer Center, which has 1,884 total studies on file at ClinicalTrials.gov.
The record links to 3 conditions, with Multiple Myeloma appearing as the primary indexed condition, and to 3 interventions - of which Acupuncture is the first listed.
NCT04459416 reports 3 study locations spanning 2 distinct geographic areas - top geographies include Washington, New York.
Frequently Asked Questions
What is clinical trial NCT04459416 about?
NCT04459416 is a clinical study titled "Managing Pain and Symptom Burden Caused by Chemotherapy in People With Myeloma or Lymphoma". The purpose of this study is to find out whether acupuncture treatments can reduce the need for opioid medication when managing pain caused by chemotherapy. The study will compare the effects of adding acupuncture to usual pain management with those of usual pain management alone, in reducing opioid...
What is the current status of trial NCT04459416?
This trial is currently active not recruiting. It is a Phase 3 study. The enrollment target is 299 participants. The study started on 2020-06-30. Estimated completion is 2026-06.
What conditions does trial NCT04459416 study?
This clinical trial studies the following conditions: Multiple Myeloma, Non-Hodgkin Lymphoma, Hodgkin Disease.
What interventions are being tested in trial NCT04459416?
The interventions under investigation include: Acupuncture (OTHER), Assessments (OTHER), opioid (DRUG).
Who is sponsoring clinical trial NCT04459416?
This trial is sponsored by Memorial Sloan Kettering Cancer Center, which has 1,884 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT04459416 being conducted?
This trial has 3 study locations across New York, Washington. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Multiple Myeloma
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
Olanzapine 2.5 vs 5 mg in Quadruplet Nausea/Vomiting Prophylaxis Before High-Dose Melphalan
RECRUITING · Phase 3
-
A Study to Learn About the Study Medicine Elranatamab Alone and With Daratumumab in People With Multiple Myeloma Who Have Received Other Treatments
RECRUITING · Phase 3
-
A Study to Compare Iberdomide Maintenance Versus Lenalidomide Maintenance Therapy Following Autologous Stem Cell Transplant in Participants With Newly Diagnosed Multiple Myeloma
RECRUITING · Phase 3
-
Phase 3 Study of Teclistamab in Combination With Lenalidomide and Teclistamab Alone Versus Lenalidomide Alone in Participants With Newly Diagnosed Multiple Myeloma as Maintenance Therapy Following Autologous Stem Cell Transplantation
RECRUITING · Phase 3
-
Study Assessing Activity of Intravenous (IV) Etentamig Monotherapy Versus Standard Available Therapies in Adult Participants With Relapsed or Refractory Multiple Myeloma
RECRUITING · Phase 3
-
A Study Comparing JNJ-79635322 and an Anti-B-cell Maturation Antigen (BCMA)xCD3 Bispecific Antibody in Participants With Relapsed or Refractory Multiple Myeloma
RECRUITING · Phase 3
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.